《再鼎医药Zai Lab Limited（ZLAB）2025年第一季度财务业绩和近期公司进展「NASDAQ」（英文版）（38页）.pdf》由会员分享，可在线阅读，更多相关《再鼎医药Zai Lab Limited（ZLAB）2025年第一季度财务业绩和近期公司进展「NASDAQ」（英文版）（38页）.pdf（38页珍藏版）》请在三个皮匠报告上搜索。

1、NASDAQ:ZLAB|HKEX:9688 2025.Zai Lab.All Rights Reserved.May 2025First Quarter 2025 Financial Results and Recent Corporate Updates Forward-Looking StatementsThis presentation contains forward-looking statements,including statements relating to our strategy and plans;potential of and expectations for o

2、ur business,commercial products,and pipeline programs;our goals,objectives,and priorities and our expectations under our growth strategy(including our expectations regarding our commercial products and launches,clinical stage products,revenue growth/CAGR,profitability and timeline to profitability,o

3、perating margins,and cash flow);the peak sales potential of our programs;capital allocation and investment strategy;clinical development programs and related clinical trials;expected timing and results of clinical trial data,data readouts,and presentations;risks and uncertainties associated with dru

4、g development,commercialization and outreach;regulatory discussions,submissions,filings,and approvals and the timing and scope thereof;the potential benefits,safety,and efficacy of our products and product candidates and those of our collaboration partners;the anticipated benefits and potential of i

5、nvestments,collaborations,and business development activities;the potential market opportunities of,and estimated addressable markets for,our drug candidates;our future financial and operating results;and financial guidance.All statements,other than statements of historical fact,included in this pre

6、sentation are forward-looking statements,and can be identified by words such as“aim,”“anticipate,”“believe,”“continue,”“could,”“estimate,”“expect,”“forecast,”“goal,”“intend,”“may,”“plan,”“possible,”“potential,”“target,”“will,”“would,”and other similar expressions.Such statements constitute forward-l

7、ooking statements within the meaning of U.S.federal securities laws.Forward-looking statements are not guarantees or assurances of future performance because there are inherent difficulties in predicting future results.Forward-looking statements are based on our expectations and assumptions as of th

8、e date of this presentation and are subject to inherent uncertainties,risks,and changes in circumstances that may differ materially from those contemplated by the forward-looking statements.We may not actually achieve the plans,carry out the intentions,or meet the expectations or projections describ

9、ed in our forward-looking statements,and you should not place undue reliance on these forward-looking statements.Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors,including but not limited to(1)our ability to success

10、fully commercialize and generate revenue from our approved products,(2)our ability to obtain funding for our operations and business initiatives,(3)the results of clinical and pre-clinical development of our product candidates,(4)the content and timing of decisions made by the relevant regulatory au

11、thorities regarding regulatory approvals of our product candidates,(5)risks related to doing business in China,and(6)other factors discussed in our most recent annual and quarterly reports and other reports we have filed with the U.S.Securities and Exchange Commission(SEC).We anticipate that subsequ

12、ent events and developments will cause our expectations and assumptions to change,and we undertake no obligation to update or revise any forward-looking statements,whether as a result of new information,future events or otherwise,except as may be required by law.Throughout this presentation,we use c

13、ertain acronyms and terms that are defined in the Glossary.The trademarks and registered trademarks appearing in this presentation are the property of their respective holders.2Key Accomplishments in 1Q253Notes:(1)Profitability refers to adjusted income from operations(non-GAAP),calculated as GAAP i

14、ncome(loss)from operations adjusted to exclude non-cash expenses,including depreciation,amortization,and share-based compensation.For additional information on this adjusted measure,refer to the“Reconciliation and Calculation of Non-GAAP Financial Measures”section;(2)Cash and cash equivalents,short-

15、term investments,and current restricted cash totaled$857.3 million as of March 31,2025,compared to$879.7 million as of December 31,2024.Delivered Strong Regional BusinessImmunology franchise expanded Povetacicept(APRIL/BAFF)VRDN-003(IGF-1R)Two NDAs under NMPA review KarXT for schizophrenia TIVDAK fo

16、r cervical cancerAccelerated Global Pipeline with FIC/BIC PotentialDemonstrated Path to Profitability1ZL-1222(PD-1/IL-12)Promising next-generation IL-12 immunocytokine therapyZL-6201(LRRC15 ADC)Potential FIC/BIC ADC with high affinity and specificity$857.3MStrong cash position2+22%1Q25 revenuey-o-y1

17、Q25 adj.loss from operation1-25%y-o-yNew commercial launches on track XACDURO and AUGTYROZL-1310(DLL3 ADC)To present updated data atand initiate a pivotal trial in 2H25MULTIPLE REVENUE INFLECTIONS THROUGH 2030+Key Growth Drivers Through 2030+4Q25-Profitability On TrackZL-1310(DLL3)Efgartigimod*ZL-15

18、03(IL13xIL31R)ZL-6201(LRRC15 ADC)ZL-1222(PD-1xIL-12),etc.2029-2030+20242025-20262027-20282028-$2bn Revenue ExpectedBemarituzumabPancreatic cancer*Multiple IndicationsLocal Manufacturing in ProgressGlobal assetsSchizo-phreniaPovetaciceptVRDN-003ADPUnlocking Blockbuster Potential of VYVGART and VYVGAR

19、T Hytrulothrough Execution ExcellenceWe Are Only Touching The Tip of the Iceberg10%Patientstreated today of total 170K gMG potential1Penetration is still low today40%Patientsreturned for repeated cycles1,2Patient volume rebounded in Mar/Apr2532025 Continued Efforts Expand Coverage,Extend DoT85%Targe

20、t coverage gMG potential in 25Broaden Patient AccessShape Treatment StandardsBetter Patient JourneyEnhance Supplemental Insurance CoverageExpert Consensus RecommendationFeb-25 published First expert consensusNational gMG Treatment Guidelines2025 expectedPartnerships with an NGO and a leading AI heal

21、th-tech partnerTarget to cover 40M enrollees for HytruloTarget to double HCP coverage for regular useLong-term Disease ManagementMar2530Target SIPcoverage in 2560+#SIP plans that coversVYVGART HytruloExpand hospital coverage and improve infusion centers capacityfor FcRn antagonists for gMGNotes:(1)Z

22、ai Lab estimates as of December 2024;(2)Est.%of patients treated in the prior quarter for the first cycle who returned for treatment in the current quarter;(3)Zai Lab estimates as of April 2025.Rapid,Deep,Sustained Improvements in gMGVYVGART Franchise Well Positioned as Potentially Best-in-Class FcR

23、n6Favorable Safety Profile as an FcRn Fragment40-73.3%No/minimal symptoms1Notes:(1)In the ADAPT trial,40%of efgar-treated patients reached MSE(Minimal Symptom Expression)within the first treatment cycle(4 weeks)and 44.6%cumulative MSE rate(3 cycles);47.1%at 21 weeks in ADAPT-NXT study,rising to 56.5

24、%by 126 weeks with continued treatment;73.3%cumulative MSE rate after 9 months of multi-cycle treatment in a real-world Chinese study;(2)Global Phase 3 ADAPT trial data;(3)Global Phase 3 ADAPT NXT study,presented at 2024 AAN;(4)Zai Lab plans to submit a CMC variation for VYVGART PFS in China in gMG

25、and CIDP in 2025;(5)Indications in development(or planned)in pivotal stage in China include seronegative gMG,ocular MG,TED,myositis and Sjogrens Disease.Precision IgG degradationConvenient and Flexible AdministrationNo albumin reduction or lipid elevationCycles-based or Q2W3enabling individualized t

26、reatmentwith SC and PFS4Pipeline-in-a-Product Opportunity2Launchedindications in China5Indications in pivotal stage in China5Significant First-to-Market AdvantageFirst and only FcRnCovered by NRDL in 2024-2025MSE=MG-ADL score of 0 or 173.0%3-point MG-ADL improvement2At week 463.3%MG-ADL reduction vs

27、.baseline3At week 21Self-administration Early and sustained reduction of positive and negativesymptoms No boxed warningand no atypicalantipsychotic class warnings Positive China Ph3 study supporting commercial uptake 8 million patients with schizophrenia in China1COMINGSOONKarXT Potential to Redefin

28、e Schizophrenia Treatment7Relapse in first year after discharge3Discontinue treatment in the first 18 months275%35%x Lack of novel MOAx Poor negative symptom controlx Unacceptable side effectsSchizophrenia:High Unmet NeedsPreparing for Potential LaunchFDA Approved;first new MoA in decades for schizo

29、phrenia500 Top hospitals150 Sales reps at NRDL85%Business potential4Efficient approach for concentrated marketLocal manufacturing plan initiatedwith strong government support in mental health85%Treatment ratio goal in 20305#of psychiatrists(per 100K population)202520304.04.5China NDA accepted in Jan

30、25Notes:Zai Lab Market Analysis.(1)Prevalence of mental disorders in China:a cross-sectional epidemiological study.The Lancet Psychiatry,2019;(2)China schizophrenia treatment guideline(version 2),May 2015;(3)https:/pubmed.ncbi.nlm.nih.gov/26056450/;(4)Zai Lab analysis;(5)Healthy China Action Plan(20

31、19-2030).20192.6Bemarituzumab Only FGFR2b-Targeted Agent in Late-Stage Development8Addressable Patient Population in China359Kest.gastric cancer annual incidence1108Kest.30%FGFR2b overexpression2Large Unmet Medical Needs80%patients diagnosed at advanced or metastatic stage3with 20 xTotal addressable

32、 patientsvs.gMG24Potential New Indications gMG170KCIDP50KOcular MG44KMyositis(IMNM,ASyS,DM)170KThyroid Eye Disease1MnSjogrens Disease2.3MnLupus Nephritis320KNeurologyRenal&RheumatologyOphthalmology&EndocrinologyDepartment FocusSources:(1)Karuna corporate presentation,May 2023;Zai Lab announcement,Oc

33、tober 2024;(2)Leucht S,Cipriani A,Spineli L,et al.Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia:a multiple-treatments meta-analysis.Lancet.2013;382(9896):951-962.EMERGENT-1KarXT(n=83),placebo(n=87)11.6-point reduction at Week 5(-17.4 KarXT vs.-5.9 placebo)Cohens d

34、effect size=0.759.6-pointreduction at Week 5(-21.2 KarXT vs.-11.6 placebo)Cohens d effect size=0.618.4-point reduction at Week 5(-20.6 KarXT vs.-12.2 placebo)Cohens d effect size=0.60PANSS total change from baselinePANSS total change from baselinePANSS total change from baselineBaselineWeek 2Week 4

35、Week 5BaselineWeek 2 Week 3 Week 4 Week 5BaselineWeek 2 Week 3 Week 4 Week 5Cohens d effect size compares favorably with other trials of antipsychotics(0.35 0.58)2EMERGENT-2KarXT(n=117),placebo(n=119)EMERGENT-3KarXT(n=114),placebo(n=120)*p0.05*p0.01*p0.0001Primary Endpoint:Change in Baseline PANSS T

36、otal Score vs.Placebo at Week 51PlaceboKarXTKarXT Robust Antipsychotic Effect across All Registrational Trials in SchizophreniaChina bridging study:9.2-point reduction at Week 5(-16.9 KarXT vs.-7.7 placebo)25LocationsPANSS PositiveSubscore(Week 5)PANSS NegativeSubscore(Week 5)KarXTPlaceboDeltaKarXTP

37、laceboDeltaEMERGENT-1US-5.6-2.43.2p0.0001-3.2-0.92.3p0.001EMERGENT-2US-6.8-3.92.9p0.0001-3.4-1.61.8p0.01EMERGENT-3US+Ukraine-7.1-3.63.5p0.0001-2.7-1.80.8p=0.12China Phase 3 StudyChina-6.5-4.61.9p=0.0474-3.2-0.72.5p=0.0062Note:*Updated results presented by Karuna in May 2023 at American Society of Cl

38、inical Psychopharmacology.In a pooled analysis of Phase 3 EMERGENT-2 and EMERGENT 3 studies,patients with cognitive impairment of greater than one standard deviation below normative standards at baseline,KarXT showed a statistically significant(p0.01)improvement in cognition from baseline with an ef

39、fect size of 0.52.KarXT is generally well-tolerated across EMERGENT-1/2/3 and China Phase 3 studyTEAEs(5%)mild to moderate in severity,mostly cholinergic and resolving over time with repeated dosingNot associated with common AEs of atypical antipsychotics(weight gain,EPS,somnolence)No unexpected saf

40、ety signals in China bridging studyKarXT Improvement in Positive,Negative and Cognitive Symptoms of Schizophrenia,with Consistent Safety/Tolerability ProfileClinically Meaningful Reductions on Key Secondary Endpoints26KarXT showed a statistically significant(p0.01)improvement in cognition from basel

41、ine with an effect size of 0.52 in a pooled analysis of EMERGENT-2 and EMERGENT-3 studies*XACDURO First Pathogen-Targeted Therapy Addressing Acinetobacter Baumannii Infections27Acinetobacter infections3Significant Unmet Need in China300KHigh carbapenem-resistant rate;antibiotic resistance is increas

42、ing53%(CARSS)3/74%(CHINET)4Carbapenem-resistant Acinetobacter is considered a Priority 1 pathogen by WHO2Acinetobacter baumannii-among the top six leading pathogens globally for deaths associated with resistance in 20191An Important Therapeutic Option Against AcinetobacterLimited therapeutic options

43、:Polymyxin-based polypharmacyColistin:drug of last resort(nephrotoxicity)Mortality rate 43%with best available therapy(Eastern Asia)5A novel treatment option:Significant difference in clinical cure rates Favorable safety profileCommercially launched in China in Jan25Notes:(1)Antimicrobial Resistance

44、 Collaborators.Global burden of bacterial antimicrobial resistance in 2019:a systematic analysis.Lancet.2022;399(10325):629-655.https:/ Health Organization,“WHO publishes list of bacteria for which new antibiotics are urgently needed,”February 27,2017:https:/www.who.int/news/item/27-02-2017-who-publ

45、ishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed;(3)CARSS(China Antimicrobial Resistance Surveillance system),2022 Annual Report;(4)Report of China Antimicrobial Surveillance Network(CHINET)in 2023;(5)Mohd 2021Sazlly Lim S,et al.The global prevalence of multidrug-resistance among

46、 Acinetobacter baumannii causing hospital-acquired and ventilator-associated pneumonia and its associated mortality:A systematic review and meta-analysis.J Infect.2019 Dec;79(6):593-600.XACDURO Stat.Higher Clinical Cure Rate and Favorable Safety Profile28First FDA and NMPA approved pathogen-targeted

47、 therapy to treat HABP/VABP caused by ABCVS.19.0%vs.32.3%colistin28-day all-cause mortality(primary endpoint)61.9%vs.40.3%colistinfor clinical cure rates13.2%vs.37.6%colistinnephrotoxicityGlobal Phase 3 ATTACK trial(vs.colistin)3ColistinTigecyclineClinical Efficacy Poor efficacy in pneumonia1Poor ef

48、ficacy in pneumonia,black box warning2Safety/TolerabilityNephrotoxicityGI intolerance Emergence of pan-drug-resistant Acinetobacter Combination antibiotic therapy not proven effective Colistin or tigecycline is most commonly used for carbapenem-resistant Acinetobacter infections(CRAB)in ChinaSources

49、:Zai Lab analysis;Entasis press release,May 2023.Notes:The trademarks and registered trademarks within are the property of their respective owners.(1)Mortality associated with colistin-based therapy is 40%(95%CI:32%to 47%);(2)Warning in US Product Labellower cure rates and higher mortality in ventil

50、ator-associated pneumonia;(3)Kaye KS,et al.Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex:a multicentre,randomised,active-controlled,phase 3,non-inferiority clinical trial(ATTA

51、CK).Lancet Infect Dis.2023 May 11:S1473-3099(23)00184-6.Current Treatments Have Poor Efficacy and TolerabilityOther Late-Stage FIC/BIC Assets to Support Near to Mid-Term Growth29Potential Best-in-Class ROS1/NTRK Inhibitor ROS1 Prevalence:23%of NSCLC patients1 Opportunity to roughly double ROS1 sales

52、 basedon:First and Only U.S.Approved ADC for r/m Cervical Cancer China:110K incidence/59K deaths every year in CC3 Limited treatment options for patients with disease progression on or after chemotherapy NCCN recommendation as a preferred option4 Full FDA approval based on global Phase 3 innovaTV 30

53、1 study5;consistent results from China subpopulationSuperior OS extension,including PD-1/PD-L1 pretreated patientsTolerable safety profile Pipeline-in-a-product,broad development program in front line cervical cancer and other solid tumors Applied in the Greater Bay Area;NMPA acceptance in 1Q 2025Hi

54、gher response rate&longer DOR2mPFS 35.7 mos in ROS1-TKI na ve (vs.20 mos of current SOC)Clinically differentiated profile in NSCLC(TKI-pretreated activity and CNS activity)Well-tolerated and manageable safety profileSources:Bristol Myers Squibb presentation,January 2023;Zai Lab analysis.Notes:The tr

55、ademarks and registered trademarks within are the property of their respective owners.(1)Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations,2014;and Frost&Sullivan;(2)AUGTYRO Prescribing Inf

56、ormation.Augtyro U.S.Product Information.Last updated:November 2023.Princeton,NJ:Bristol Myers Squibb Company;(3)Globocan 2020;CSCO treatment guideline for cervical cancer,2023;(4)NCCN 2024,for 2L or subsequent therapy for r/m cervical cancer;(5)The innovaTV 301 study demonstrated a 30%reduction in

57、the risk of death compared to chemotherapy(hazard ratio HR:0.70 95%CI:0.54-0.89,two-sided p=0.0038).Median OS for patients treated with TIVDAK was 11.5 months 95%CI:9.8-14.9 versus chemotherapy 9.5 months 95%CI:7.9-10.7.Leverage Zais Existing R&D and Commercial CapabilitiesDe-risked MoA with Promisi

58、ng Clinical Data30Highly synergisticwith Zais VYVGART franchiseChina already joined poves global pivotal trial in IgANEst.35 million prevalent patients in China in IgAN aloneSignificant Unmet Needs in Renal DiseasesDual inhibition of BAFF/APRIL clinically validatedNo approved therapies target the un

59、derlying cause of IgANCompelling Phase 2 data supports poves best-in-class profilePovetacicept(APRIL/BAFF)Potentially Transformative Approach to IgANZai Lab Brings Regional Expertise and Footprint to Accelerate Patient Access to Povetacicept1A Phase 3 and Potentially Transformative Approach to IgAN

60、with Best-in-Class and Pipeline-in-a-Product PotentialSources:Chinese expert consensus on the management and treatment of primary IgA nephropathy.Chinese Journal of Kidney Disease Investigation(Electronic Edition),February 2024,Vol 13,No.1;Zai Lab market research.(1)Development and commercialization

61、 of pove in mainland China,Hong Kong SAR,Macau SAR,Taiwan region and Singapore(the licensed territory).Povetacicept(APRIL/BAFF)Compelling RUBY-3 data(ASN 2024)31Updated RUBY-3 Data Continue to Demonstrate Best-In-Class PotentialAt 48 weeks,pove 80mg SC Q4W:66%mean reduction in UPCR Stable renal func

62、tion as assessed by eGFR 63%achievement of clinical remission,defined as UPCR 0.5 g/g,negative hematuria,and stable renal functionSource:Vertex Corporate Presentation(Third Quarter 2024 Financial Results),November 4,2024.Note:Mean and standard error are based on geometric values.Zai Lab and Vertex c

63、ompleted enrollment of the interim analysis cohort in the global Ph3 RAINIER study.Zai Lab participated in the study in Greater ChinaVRDN-003(SC)Veligrotug and VRDN-003(IGF-1R)Positive Phase 3 Results Support the Transformative Potential in Thyroid Eye Disease32Note:Adapted from Viridian Therapeutic

64、s Corporate Presentation,May 2025.Sources:(1)Zai Lab market research;(2)Viridian THRIVE data on file;(3)Viridian THRIVE-2 data on file;(4)Planned product profile,including planned clinical dosing regimen.Current TED Market(China)Veligrotug(IV)Primed for new entrants and growthWell-positioned to beco

65、me the IV treatment-of-choice in TEDSubcutaneous and potential best-in-class therapy in TED1 million patients diagnosed with moderate-to-severe forms of TED in China17080%are chronic TED1No subcutaneous optionavailable commerciallyRobust and consistent clinical responses in active and chronic TED2,3

66、Rapid onset of treatment effect2,3First demonstration of diplopia response and resolution in a global chronic TED Ph3 study3Generally well tolerated2,3Significantly reduced treatment burden2,3Infrequent administration of every 4 or 8 weeks4Designed to replicate veligrotug clinical profile4Potential

67、to greatly expand TED market,if approvedTopline data of global Ph3 studies expected in 1H 2026Zai Lab plans to advance VRDN-003(SC)into a China registrational study for TED,as a potentially best-in-class,long half-life and convenient subcutaneous anti-IGF-1R15%SCLC1Worldwide 372,000 newly diagnosed

68、patients with SCLC each year1,234,0001,273,0001,2Highly aggressive disease associated with poor survival outcomesNotes:(1)J Thorac Oncol.2023 Jan;18(1):31-46;Lung Cancer Foundation of America;(2)WHO Globocan 2022;(3)Sabari JK,et al.Nat Rev Clin Oncol.2017;14:549-561;(4)National Cancer Institute.www.

69、cancer.gov.Accessed October 15,2024;(5)Phase 3 IMpower133(atezolizumab)and CASPIAN study(durvalumab).Lung Cancer2/3 diagnosed with ES-SCLC3510%overall survival at 5 years41L Despite addition of I/O,current SOC has limited improvement in survival(mOS 1213 mos)52L+Tarlatamab recently added;room for im

70、provement in efficacy,safety and easier community setting accessLimited Treatment Options and Significant Unmet Needs Remain for ES-SCLCZL-1310 Significant Unmet Needs for Patients with SCLCGlobal Ph1ZL-1310 Potential Global First-in-class ADC Targeting DLL3(ENA 2024)Key Efficacy Results(n=19)74%ORR

71、(14/19)1with anti-tumor activity across all dose levels 100%ORR(6/6)in patients with brain metastases One patient with prior tarlatamab failure achieved a partial response with a 67%tumor reduction 13 of 14 responders ongoing including patients treated at the lowest dose(0.8 mg/kg)Key Safety Results

72、(n=25)Well tolerated across all dose levels with majority of TEAEs being Gr 1 or 2 20%Gr3 TRAEs,8%serious TRAEs,no CRS and ICANS No dose discontinuation or death due to TEAESource:Zai Lab presentation,ZL-1310 ENA 2024 Highlights,October 24,2024.Notes:(1)Data shared in the ENA presentation from the o

73、ngoing Part 1a monotherapy dose-escalation portion of the study included results from 25 patients across four dose cohorts(0.8 mg/kg,1.6mg/kg,2.0 mg/kg,and 2.4 mg/kg).Data cut-off:October 10,2024.Nineteen patients had evaluable tumor assessments,included 5 patients with confirmed partial response(PR

74、)and 9 patients with unconfirmed PR(responses are ongoing at data cutoff).of all patients received at least two prior regimens of systemic therapyof patients received prior anti-PD-(L)1 therapy56%92%Baseline CharacteristicGlobal Ph1Our patient-first core value drives us to impact human healthOur ESG

75、 approach and growing pipelinehelp us create better outcomes foreveryoneTarget:Maintain gender equity in leadership and base payWe build trust by acting urgently and ethicallyTarget:Complete ERM top-tier risk mitigationplans annuallyOne MillionPatients by2030*Trust for LifeImproveHumanHealthCreate B

76、etter OutcomesAct Right NowNote:*Target for“Improve Human Health”.Our ESG Trust for Life Strategy,Commitments,and Targets35Glossary:A-H361Lfirst line2Lsecond line4L fourth line3Q22third quarter of 20223Q23third quarter of 20233Q24third quarter of 20244Q24fourth quarter of 2024FY24full year of 20241H

77、25first half of 20252H25second half of 2025q-o-qquarter-over-quartery-o-yyear-over-yearAABCacinetobacter baumannii-calcoaceticus complexABSSSIacute bacterial skin and skin structure infectionsAChR-Abacetylcholine receptor autoantibodyADatopic dermatitisADCantibody-drug conjugateADCCantibody-dependen

78、t cellular cytotoxicityADLactivities of daily livingADPpsychosis associated with Alzheimers diseaseAEadverse eventaINCATadjusted inflammatory neuropathy cause and treatmentASySanti-synthetase syndromeBBDbusiness developmentBICbest-in-classBICRblinded independent central reviewBLABiologics License Ap

79、plicationBORbest overall responseCCABPcommunity-acquired bacterial pneumoniaCAGRcompound annual growth rateCASClinical Activity ScoreCCcervical cancerCIconfidence intervalCIDPchronic inflammatory demyelinating polyneuropathyCMIclinical meaningful improvementCombocombination therapycORRconfirmed obje

80、ctive response rateCPPchronic plaque psoriasisCRcomplete responseCRDcysteine-rich domainCRScytokine release syndrome DDARdrug-antibody ratioDEIdiversity,equity,and inclusionDMdermatomyositisDORduration of responseDoTduration of treatmentEEADVEuropean Academy of Dermatology and Venerology CongressENA

81、European Neurological AssociationEPSextrapyramidal symptomsES-SCLCextensive-stage small cell lung cancereGFRestimated glomerular filtration rateFFDAU.S.Food and Drug AdministrationFGFfibroblast growth factorFICfirst-in-classGGBMglioblastomaGCgastric cancerGEJgastroesophageal junction cancerGIgastroi

82、ntestinalGISTgastrointestinal stromal tumorsgMGgeneralized myasthenia gravisHHABP/VABPhospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumoniaHCPhealthcare professionalHemOnchematological oncologyHRhazard ratioGlossary:I-Y37IICANSimmune effector cell-associated neurotoxici

83、ty syndrome ICIimmune checkpoint inhibitorIgANimmunoglobulin-a nephropathyIHCimmunohistochemistryIMNMimmune-mediated necrotizing myopathyINDInvestigational New Drug applicationISDindividualized starting doseITTintention-to-treatIVintravenousIVIGintravenous immunoglobulinI/Oimmuno-oncologyLLAPClocall

84、y advanced pancreatic cancerLDLlow-density lipoproteinLLNlower limit of normalLNlupus nephritisMMAAMarketing Authorization ApplicationMDRmulti-drug resistancemedical repsmedical representativesMGmyasthenia gravisMild-to-Modmild to moderateMOAmechanism of actionMod-to-Sevmoderate to severemonomonothe

85、rapymOSmedian overall survival mPFSmedian progression-free survivalNNDANew Drug ApplicationNEnot estimableNECNeuroendocrine carcinomaNMPAChinas National Medical Products AdministrationNRDLChinas National Reimbursement Drug ListNSCLCnon-small cell lung cancerNSCLC BMbrain metastases from NSCLCOOCovar

86、ian cancerOMGocular myasthenia gravisORRobjective response rateOSoverall survivalPPANSSPositive and Negative Syndrome ScalePASIPsoriasis Area Severity IndexPCpancreatic cancerPDprogressive diseasePFSpre-filled syringePh1phase 1Ph2phase 2Ph3phase 3PLEXplasma exchangepMNprimary membranous nephropathyP

87、Oper osPRpartial responseQQoLquality of lifeRR&Dresearch and developmentr/mrecurrent or metastaticRCTrandomized clinical trialSSCsubcutaneousSCLCsmall cell lung cancerSDstable diseaseSG&Aselling,general,and administrativeSIPsupplemental insurance plansn gMGseronegative gMGSOCstandard of careTTAtherapeutic areaTCET-cell engagerTEAEtreatment-emergent adverse eventTEDthyroid eye diseaseTFtissue factorTKItyrosine kinase inhibitorTOP1itopoisomerase 1 inhibitorTRAEtreatment-related adverse eventTTFields/TTFTumor Treating FieldsUULNupper limit of normalUPCRurine protein to creatinine ratio